The double-digit million Euro investment is designed to increase the production of ready-to-use (RTU) vials in Lebanon, Pennsylvania.
The vials are pre-washed and sterilized, and packaged in a standardized tub to simplify the filling process for pharmaceutical companies.
SCHOTT provides a comprehensive product portfolio for RTU vials with more than 750 product combinations.
As a globally trusted partner for advanced drug containment and delivery solutions, SCHOTT is announcing plans to triple its vial production capacity at its site in Lebanon, PA. In doing so, the international technology company will further strengthen its business for ready-to-use (RTU) solutions, which have emerged as an often preferred drug containment alternative for high-value medications. “With our investment, we are underlining our commitment to the global pharma industry and particularly the U.S. market. Additionally, we are enhancing our regional manufacturing footprint in Lebanon, Pennsylvania, where we are proudly celebrating our site’s 30th anniversary,” said Andreas Reisse, Executive Vice President of SCHOTT Pharma.
The RTU vials known under the brand name adaptiQ® are particularly suitable for drugs, such as biologics and vaccines, including upcoming technologies like mRNA-based drugs. The solution enables pharma companies to efficiently perform pre-clinical and clinical trials as well as commercial filling. “We are increasing our production capacity intending to meet the growing need for this product category and contribute to bringing the latest life-saving treatments to patients faster,” said Hakan Gerdan, who was appointed as SCHOTT’s new Plant Manager in Lebanon, PA at the start of 2022.
About SCHOTT Pharma’s RTU portfolio
As part of the SCHOTT iQ® platform, the company’s RTU vials are delivered to customers pre-washed and pre-sterilized, to allow pharma companies to focus on their core competencies of developing and filling life-saving drugs in a timely manner. The adaptiQ® vials are made from FIOLAX® Type I borosilicate glass, which is considered the gold standard for packaging pharmaceuticals. During the filling process, the vials remain fixed in a standardized tub, which is the same tub also utilized for other drug containment and delivery solutions such as prefillable syringes and cartridges. The use of a standard tub simplifies the filling process for pharma companies as it offers greater flexibility when switching between different drug containment solutions, thereby reducing costs and time-to-market.
With its adaptiQ® brand, SCHOTT is able to provide a comprehensive product portfolio featuring more than 750 product combinations for RTU vials. Available in standard ISO sizes ranging from 2R to 50R, the vials can be offered with a number of premium performance enhancements, including:
EVERIC® pure providing outstanding drug compatibility and delamination resistance
SCHOTT Type I plus® suitable for highly sensitive biologics
SCHOTT TopLyo® designed for superior performance for lyophilized drugs
Amber Color Glass protecting light sensitive pharmaceutical products
Fabian Stöcker, Vice President for the Sterile Solutions division of SCHOTT Pharma, and Christopher Cassidy, Vice President at SCHOTT North America, Inc., noted in unison, “The breadth of our RTU vial portfolio provides biopharma customers with the widest selection of sizes, formats, and performance capabilities. This is how we help find the proper container for the many unique and demanding drug products being developed today.” Based on market demand, the company is open to further expand its global production footprint for RTU vials.
20.06.2022, SCHOTT
此网站新闻材料的版权属于公司或第三方的新闻提供者，其所有权利保留。所有新闻材料对其访问者只能限于其本人使用，并且使用此材料的风险由其使用者独自自行承担。严禁对新闻材料进行再次发布和其它商业利用. 作为商业贸易的用途。如果新闻材料由第三方提供，当应用此新闻材料时，每个使用者都同意遵守，并且受此特定的项目的约束。Glass Global并不代表及认可新闻材料中所包含的内容及新闻中的外部网站的内容的准确性及可靠性。
Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.